Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

David M. Holtzman

Tracked across 2 events · 34 articles · First seen Feb 19, 2026 · Last active Sep 21, 2026

Sentiment
20
Attention
6
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 30
Tech
Impact: David M. Holtzman is a co-founder of C2N Diagnostics and a coauthor of the study, contributing to the development of the blood test.
Feb 19, 2026 · 6 articles
4 10
Tech
The U.S. United States — Food and Drug Administration cleared the PrecivityAD2 blood test, developed by C2N Diagnostics, a startup founded by researchers at Washington University in St. Louis, to help evaluate Alzheimer's disease in…
Impact: Co-founded C2N Diagnostics and co-led development of the technology behind the cleared PrecivityAD2 test.
Aug 21, 2026 · 28 articles
ERGEN INTELLIGENCE
Track David M. Holtzman live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.